SCHEMBL6790307

SCHEMBL6790307

COC(=O)c1cc(OC)c(C)cc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.58
LTB4R Q15722 1/20 0.47
KDM4E B2RXH2 8/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 7/20 0.46
HPGD P15428 3/20 0.46
POLB P06746 1/20 0.46
GAA P10253 3/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 1/20 0.44
HTT P42858 2/20 0.43
ALOX12 P18054 1/20 0.43
LMNA P02545 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6781638 0.93 TERT (0.61) TERTLTB4RKDM4EHSD17B10MAPK1
SCHEMBL4026499 0.92 TERT (0.67) TERTLTB4RKDM4EHSD17B10ALDH1A1
SCHEMBL6784696 0.88 TERT (0.67) TERTLTB4RKDM4EHSD17B10MAPK1
SCHEMBL6790891 0.85 KDM4E (0.59) TERTLTB4RKDM4EHSD17B10MAPK1
SCHEMBL6783723 0.84 KDM4E (0.46) TERTLTB4RKDM4EHSD17B10MAPK1
SCHEMBL6785982 0.84 ALDH1A1 (0.46) LTB4RKDM4EHSD17B10MAPK1ALDH1A1
SCHEMBL6781951 0.84 KDM4E (0.60) TERTLTB4RKDM4EHSD17B10MAPK1
SCHEMBL4021468 0.84 TERT (0.71) TERTLTB4RKDM4EHSD17B10MAPK1
SCHEMBL6782055 0.84 TERT (0.65) TERTLTB4RKDM4EHSD17B10ALDH1A1
SCHEMBL6782397 0.84 TERT (0.64) TERTLTB4RKDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885LTB4R 3433/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.